Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
.svg) | |
| Long title | To authorize the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law, and for other purposes. |
|---|---|
| Nicknames | Right to Try Act |
| Enacted by | the 115th United States Congress |
| Citations | |
| Public law | Pub. L. 115–176 (text) (PDF) |
| Statutes at Large | 132 Stat. 1372 |
| Legislative history | |
| |
The Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (S. 204, Pub. L. 115–176 (text) (PDF)), also known as the Right to Try Act, is a United States federal law which allows experimental drugs to be administered to terminally ill patients who have exhausted all approved treatment options and are unable to participate in clinical drug trials. All eligible drugs must have undergone the Food and Drug Administration's (FDA) Phase I (safety) testing. The law seeks to increase access to experimental drugs by allowing patients, through their physicians, to request experimental medicines directly from drug manufacturers without involving the FDA.[1] The FDA's expanded access program exists in parallel to the Right to Try Act. There is no legal obligation for drug manufacturers to provide their investigational products to patient who seek them.[2]
References
- ^ Howard, Jacqueline (March 22, 2018). "What you need to know about right-to-try legislation". CNN. Retrieved September 30, 2023.
- ^ Commissioner, Office of the (January 17, 2023). "Right to Try". FDA.
 | This United States federal legislation article is a stub. You can help Wikipedia by expanding it. |